The TGF-β family of cytokines influences a diverse repertoire of cellular processes, including cell proliferation, differentiation, survival and synthetic activity. One of three TGF-β ligand isoforms (TGF-β1, TGF-β2 or TGF-β3) initiates signaling by binding to the TGF-β receptor complex, which is composed of type 1 and type 2 receptor subunits (TβR1 and TβR2, respectively) 11 .
l e t t e r s
An excess of canonical TGF-β signaling has also been shown in the aortic wall of individuals with LDS 2 . However, this finding has been difficult to reconcile with the character of the underlying mutations in this syndrome. LDS is predominantly caused by heterozygous missense substitutions affecting the kinase domain of either TβR1 or TβR2 (encoded by the TGFBR1 and TGFBR2 genes, respectively) 2, 5 . When mutant proteins are expressed in cells that are naïve for the corresponding receptor subunit, the cells are unable to propagate SMAD-dependent TGF-β signaling 21 . More rarely, LDS-like phenotypes can be caused by haploinsufficiency for SMAD3 or the TGFB2 gene encoding the TGFβ2 ligand, positive effectors of TGF-β signaling 22, 23 . Notably, heterozygous loss-of-function mutation in SMAD3 or TGFB2 associates with high TGF-β signaling in the aortic wall of both affected humans and mouse models 22, 23 . Taken together, these seemingly contradictory data have engendered considerable controversy regarding the precise role of TGF-β in the pathogenesis of aortic aneurysm.
SGS is a systemic connective tissue disorder of unknown etiology that includes virtually all the craniofacial, skeletal, skin and cardiovascular manifestations of MFS and LDS, with the additional findings of mental retardation and severe skeletal muscle hypotonia 6, 8 . We hypothesized that aberrant TGF-β activity also underlies SGS and that identification of the genetic basis of this syndrome would inform our understanding of other syndromic presentations of aneurysm 2 . We performed whole-exome sequencing for a single trio comprising a child with SGS and the unaffected parents. An average of 6.9 Gb of sequence was generated per individual as paired-end 75-bp reads, out of which >98.9% mapped to the human reference genome (UCSC hg19). This analysis identified only one variant, a heterozygous missense change in exon 1 of the SKI gene (c.347G>A, p.Gly116Glu; NM_003036) that was not present in SNP databases, was predicted to be damaging (PolyPhen-2 score of 0.999, SIFT score of 0.05), was not present in either parent and was a strong functional candidate because of a described relationship to TGF-β signaling ( Supplementary  Fig. 2) 24, 25 . We subsequently sequenced SKI in 11 other sporadic cases of SGS ( Fig. 1a and Table 1 ) and identified heterozygous variants in 9 of these individuals, including 8 missense mutations and a 9-bp deletion (Supplementary Fig. 3 ). These mutations were absent from dbSNP134, the 1000 Genomes Project database and over 10,000 exomes reported on the National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server, and they were confirmed to be de novo when testing of the unaffected parents was possible (for 5 of 9 affected individuals). Collectively, ten mutations in ten individuals with SGS were identified in SKI by a combination of whole-exome and Sanger sequencing, including a recurrent mutation in two unrelated probands. Each mutation resulted in the substitution or deletion of amino acids that show complete evolutionary conservation in members of the SKI gene family (Supplementary Fig. 4 ) 26 . No mutations were identified in sequencing of SKIL (NM_005414) in the two remaining affected individuals. The alterations in SKI clustered in two distinct N-terminal regions of the protein (Fig. 1b) . The first region is located in the SMAD2/3-binding domain of SKI (residues 17-45), and npg l e t t e r s the second region localizes to a portion of the Dachshund-homology domain (DHD) of the SKI protein that mediates binding to SNW1 and N-CoR, proteins that are essential for the transforming activity of SKI and for the recruitment of transcriptional corepressors, such as histone deacetylases, respectively 15, 27, 28 . One of the alterations (p.Leu21Arg) results in the substitution of an amino acid that was previously shown to be essential for SKI-SMAD3 interaction 29 . Two of the alterations (p.Gly116Glu and p.Gly117Arg) result in substitutions at immediately adjacent glycine residues at positions that contribute to an exposed β hairpin loop in the DHD 30 . In silico analysis suggests that both glycine substitutions maintain the β turn; whereas there is variation in where the I-TASSER structural prediction algorithm 31 defines the margins of the adjacent β sheets, the overall structures of the DHD are fully overlapping for the reference and mutant sequences ( Supplementary Fig. 5 ). It is therefore possible that the primary consequence of these alterations is disruption of molecular interactions at the protein surface. In light of this observation, it is noteworthy that residues 125-131, which lie immediately distal to the β turn, have been shown to influence binding of SMAD2/3 to their more proximal N-terminal binding site 30, 32 .
To assess the functional consequences of SKI mutations identified in SGS, we monitored TGF-β signaling in primary dermal fibroblasts derived from two individuals with SGS and two control individuals. Protein blot analysis showed excessive SMAD2/3 and ERK1 and ERK2 (ERK1/2) phosphorylation in the cells of the affected individuals compared to controls, both at baseline and after acute (30-min) stimulation with exogenous TGF-β2 (Fig. 2a) . This implies loss of suppression of the TGF-β-dependent signaling cascades in SGS cells. In contrast, there was no difference in the activation of c-Jun N-terminal kinase (JNK) or p38 between SGS and control cells at baseline or in response to TGF-β2. The alterations in canonical TGF-β and ERK signaling directly parallel previous findings in the aortas of both affected humans and mouse models of MFS and LDS 4, 23 . We also observed a significant increase in mRNA expression for TGF-β-dependent genes in SGS fibroblasts relative to controls, including COL1A1, COL3A1, FN1, VIM and CDKN1A (encoding collagen type 1, collagen type 3, fibronectin, vimentin and p21, respectively) (Fig. 2b) . This is in keeping with previous work showing that transcription of these genes is normally suppressed by SKI 33 . TGF-β also induces transcription of genes encoding negative regulators of the TGF-β pathway, including SKI, SKIL and SMAD7, as part of an autoregulatory loop. We observed higher mRNA expression of each of these genes in SGS cells compared to controls, suggesting that SKI normally suppresses the expression of itself as well as other negative regulators of TGF-β signaling. Notably, the TGF-β-regulated target genes CTGF and SERPINE1 npg l e t t e r s showed equivalent expression in SGS and control cells, suggesting either gene-specific differences in their sensitivity to attenuation of SKI function or to the regulatory influence of other transcriptional repressors such as SKIL or SMAD7. Despite the near-complete phenotypic overlap between LDS and SGS, it is notable that the aneurysm phenotype in SGS is less penetrant, less diffuse (generally restricted to the aortic root) and less severe than that seen in LDS. We reasoned that this might relate to the temporal and regional expression pattern of SKI. To test this hypothesis, we performed a developmental survey of SKI expression in wild-type mice (Fig. 3a) . At embryonic day (E) 13.5, SKI protein was robustly expressed throughout the vessel wall in the proximal ascending aorta with less expression in the descending segment and was localized to both the cytoplasm and nucleus. At birth (postnatal day 0, P0), aortic expression was somewhat reduced, and SKI was predominantly localized to the cytoplasm. In adult mice (P90), SKI expression was further reduced in the medial layer of the aortic root, with exclusive cytoplasmic localization; in the more distal ascending aorta, SKI expression was largely excluded from the central zone of the aortic media, despite some residual expression in the intimal and adventitial layers. Taken together, these data support the hypothesis that SKI may predominantly be required in the very proximal aorta at early stages of development for the proper regulation of TGF-β signaling within the arterial media.
We show that the multisystem manifestations of SGS are caused by primary mutations in a prototypical repressor of TGF-β signaling and that these mutations associate with a cell-autonomous increase in SMAD2/3 activation at steady state and in the acute phase response to TGF-β ligand, as well as with increased transcriptional output of TGF-β-responsive genes. It remains to be determined whether the increased ERK1/2 activation seen in SGS cells represents loss of a previously unrecognized direct function of SKI or indirect cellular events.
The conclusion that release from the suppressive effects of SKI on TGF-β signaling underlies SGS is consistent with previous observation of central nervous system (CNS) patterning alterations, skeletal muscle hypoplasia and craniofacial defects (all cardinal manifestations of SGS) in homozygous Ski-targeted mice 34 . It is further strengthened by our ability to replicate SGS-like defects after morpholino-based knockdown of the two paralogs of mammalian SKI (skia and skib) in zebrafish. skia-and skib-morphant zebrafish embryos showed marked craniofacial cartilage deficits, including shortened and flat Meckel's cartilage, irregular lengths of palatoquadrates, shortened ceratohyales and depleted ceratobranchial arches ( Fig. 3b and Supplementary Table 1) . These deficits manifest in larval fish as maxillary hypoplasia, malformed ethmoid plate, micrognathia and microcephaly and are frequently accompanied by ocular hypertelorism and spinal malformations. Furthermore, skia-and skibmorphant embryos showed severe cardiac anomalies, characterized by partial-to-complete failure in cardiac looping and malformations of the outflow tract (Fig. 3b and Supplementary Table 1) .Thus, in comparison to Ski-null mice, the zebrafish morphants more closely recapitulate the human SGS craniofacial phenotype and uniquely imply that there is a requirement for SKI in early cardiovascular development. Previous findings of a prominent role for SKI in both neurogenesis and myogenesis reconcile the highly penetrant developmental delay and hypotonia seen 
Baseline 30 (a) Protein blot analysis of phosphorylated SMAD2 (pSMAD2), SMAD3 (pSMAD3), ERK1/2 (pERK1/2), JNK 1 and JNK2 (pJNK1/2) and p38 (pp38) and β-actin (loading control) at steady state (baseline) and in response to TGF-β2. Representative SGS and control blots are shown (for a single individual with SGS and a single control, with three biological replicates for each condition). Graphs show protein blot quantification of three biological replicates for each condition in two individuals with SGS and two controls. All protein amounts are normalized to those of β-actin. The control baseline value for each graph was set to 1.0; all other values represent fold change relative to this sample. (b) Relative mRNA expression of TGF-β target genes (normalized to ACTB levels), as assessed by quantitative PCR (qPCR) analysis. Quantification was performed on three biological replicates in each of two individuals with SGS and two controls. In the graphs in a and b, the upper and lower margins of the box define the 75th and 25th percentiles, respectively, the internal line defines the median, and the whiskers define the range. *P < 0.05; **P < 0.01; † P < 0.001; † † P < 0.0001.
npg l e t t e r s in SGS, respectively 35, 36 . It is also notable that a recurrent mutation in SMAD4 that strongly impairs TGF-β transcriptional responses by the R-SMAD-SMAD4 complex has recently been shown to cause Myhre syndrome, a condition characterized by short bones and aortic stenosis, in marked contrast to the bone overgrowth and aortic dilatation seen in SGS 37 . Persons with the recurrent 1p36 deletion syndrome are haploinsufficient for SKI and show some phenotypic overlap with SGS, including hypotonia, developmental delay, craniofacial dysmorphism, vertebral abnormalities and structural heart disease 38, 39 . Possible reasons for the features that distinguish these two conditions include the involvement of contiguous genes in the 1p36 deletion syndrome and/or the putative dominant-negative potential of mutant forms of SKI in SGS, which might retain their ability to form homodimeric complexes due to structural preservation of the SKI-interacting domain at the C terminus, with functional deficits imposed by N-terminal alterations that selectively perturb R-SMAD and/or N-CoR interactions. Substitution of neighboring cysteine residues (p.Cys1223Tyr and p.Cys1221Tyr) in an epidermal growth factor (EGF)-like domain of fibrillin-1 have been reported in association with an SGS-like phenotype, including all features of MFS and SGS-specific features, such as craniosynostosis and developmental delay 40, 41 . Although it remains to be determined whether this tentative genotype-phenotype correlation is primarily a consequence of FBN1 genotype, modifier loci or chance, it seems notable that both fibrillin-1 and SKI are recognized regulators of TGF-β signaling.
In conclusion, this manuscript provides evidence that mutations predicted and observed to enhance TGF-β signaling are sufficient to cause human phenotypes that have variably been associated with low TGF-β signaling states, including craniosynostosis, altered palatogenesis and aortic aneurysm. The development of individualized treatment strategies will require further work to determine whether low and high signaling states achieve the same phenotypic consequence or, as we propose, complex compensatory events during tissue morphogenesis and homeostasis culminate in a common pathogenic mechanism for seemingly disparate disease etiologies 42 .
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Methods and any associated references are available in the online version of the paper. Figure 3 Assessment of SKI expression in model systems. (a) Mouse SKI expression at E13.5 is high in the mitral valve (MV), tricuspid valve (TV), pulmonary trunk (Pu), pulmonary valve (PuV), bronchus (Br) and proximal aorta (Ao; both nucleus and cytoplasm). Lower expression is seen in the descending aorta (dAo), esophagus (E), right and left ventricles (RV and LV, respectively) and left atrium (LA). Red, SKI; green, myosin heavy chain; blue, nuclei. At birth (P0), SKI is expressed in the aortic root (AoR), distal ascending aorta (ascAo) and endothelial surface of the mitral valve and aortic valve (AoV), with less nuclear expression than at E13.5. In adulthood, SKI is expressed exclusively in the cytoplasm of the aortic valve and the media of the aortic root; in the ascending aorta, SKI is expressed in the intima (I) and adventitia (A) but is excluded from the central media ( 
